Key result
MicroRNAs emerge as potential targets for diabetic cardiomyopathy diagnosis, prognosis, and treatment.
Why the study?
Diabetic cardiomyopathy is associated with increased morbidity and mortality in diabetic patients, and microRNAs can act as cardioprotective or cardiotoxic agents.
Do microRNAs serve as potential biomarkers and therapeutic targets for diabetic cardiomyopathy?
Design
Literature review
Authors
Loading...
MicroRNA biomarkers should not yet change diabetic cardiomyopathy practice; leaves open their diagnostic and therapeutic utility pending prospective trials.
Do microRNAs serve as potential biomarkers and therapeutic targets for diabetic cardiomyopathy?
MicroRNAs are promising biomarkers and therapeutic targets for managing diabetic cardiomyopathy.
Rhman et al. (2022) conducted a review in Diabetic cardiomyopathy. microRNAs was evaluated. MicroRNAs serve as attractive potential targets for diabetic cardiomyopathy diagnosis, prognosis, and treatment due to their distinctive expression profile in disease development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: